195 related articles for article (PubMed ID: 6488171)
41. Effects and mode of action of Corynebacterium parvum on murine tumour metastases.
Castro JE; Sadler TE; Jones PD
Dev Biol Stand; 1977 Apr 13-15; 38():277-81. PubMed ID: 608510
[TBL] [Abstract][Full Text] [Related]
42. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
43. Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.
Lichtenstein A; Berek J
Cancer Immunol Immunother; 1986; 22(1):24-30. PubMed ID: 3708631
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
45. Effect of Corynebacterium parvum on tumor growth in the central nervous system of mice.
Conley FK; Remington JS
J Natl Cancer Inst; 1978 Sep; 61(3):827-32. PubMed ID: 278860
[No Abstract] [Full Text] [Related]
46. Effect of pregnancy on augmentation of natural killer cell activity by Corynebacterium parvum and Toxoplasma gondii.
Luft BJ; Remington JS
J Immunol; 1984 May; 132(5):2375-80. PubMed ID: 6715884
[TBL] [Abstract][Full Text] [Related]
47. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
Gabizon A; Leibovich SJ; Goldman R
J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the in-vitro antitumor activity of peritoneal cells from mice injected with Corynebacterium parvum and Corynebacterium liquefaciens.
Toge T; Hattori T
Hiroshima J Med Sci; 1979 Jun; 28(2):95-101. PubMed ID: 478988
[No Abstract] [Full Text] [Related]
49. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity.
Nasrallah AG; Gallagher MT; Priest EL; Trentin JJ
Cancer Res; 1980 Nov; 40(11):4159-64. PubMed ID: 7471057
[TBL] [Abstract][Full Text] [Related]
50. Effects of soluble mediators generated during growth of the Landschütz ascites carcinoma on the chemotaxis of normal and Corynebacterium parvum-stimulated peritoneal leucocytes.
McIntosh LC; Thomson AW
Br J Exp Pathol; 1984 Aug; 65(4):441-51. PubMed ID: 6466553
[TBL] [Abstract][Full Text] [Related]
51. Effects of Corynebacterium parvum on Escherichia coli infection in mice.
Yoshikai Y; Miake S; Mituyama M; Nomoto K
J Gen Microbiol; 1982 Dec; 128(12):2857-63. PubMed ID: 6763935
[TBL] [Abstract][Full Text] [Related]
52. Dibutyryl cyclic AMP protects Corynebacterium parvum-treated mice against lipopolysaccharide-induced lethal toxicity.
Inoue H; Takahashi S; Nomoto K; Yoshikai Y
Cell Immunol; 1995 Apr; 162(1):1-7. PubMed ID: 7704897
[TBL] [Abstract][Full Text] [Related]
53. Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization.
McCune CS; O'Donnell RW; Horan PK; Budd HS; Spennacchio JL; Chuang C; Henshaw EC
J Natl Cancer Inst; 1982 Sep; 69(3):647-52. PubMed ID: 6955557
[TBL] [Abstract][Full Text] [Related]
54. Enhancement of tissue invasion in murine aspergillosis by systemic administration of suspensions of killed Corynebacterium parvum.
Purnell DM
Am J Pathol; 1976 Jun; 83(3):547-56. PubMed ID: 779492
[TBL] [Abstract][Full Text] [Related]
55. The characteristics of binding of Corynebacterium parvum to glass-adherent mouse peritoneal exudate cells.
Ogmundsdóttir HM; Weir DM
Clin Exp Immunol; 1976 Nov; 26(2):334-9. PubMed ID: 991461
[TBL] [Abstract][Full Text] [Related]
56. [Effect of the age of the mouse on the action of Corynebacterium parvum in inhibiting the growth of 2 syngenetic tumors].
Mazureka C; Stiffel C; Chalvet H; Biozzi G
C R Seances Acad Sci III; 1981 Oct; 293(4):225-8. PubMed ID: 6794870
[TBL] [Abstract][Full Text] [Related]
57. Studies using labelled C. parvum preparations in mice.
Scott MT
Dev Biol Stand; 1977 Apr 13-15; 38():123-7. PubMed ID: 608498
[TBL] [Abstract][Full Text] [Related]
58. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
Minton JP; Rossio JL; Dixon B; Dodd MC
Clin Exp Immunol; 1976 Jun; 24(3):441-7. PubMed ID: 1084821
[TBL] [Abstract][Full Text] [Related]
59. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
60. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
